Results 61 to 70 of about 3,238 (182)

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, Volume 138, Issue 2, Page 219-228, August 2026.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Risk factors of local control in adrenal metastases treated by stereotactic body radiation therapy - a systematic review and meta-analysis

Frontiers in Oncology, 2023
PurposeThis study is aimed to explore risk factors affect the therapy outcomes of adrenal metastases (AM) for stereotactic body radiation therapy (SBRT) and guide clinical dose selection.Methods and materialsPubMed, Embase and Web of Science were ...
Xuehong Liao, Xuehong Liao, Kazushi Kishi, Kaixin Du, Kaixin Du, Ritsuko Komaki, Junetsu Mizoe, Gosuke Aikawa, Wei Zheng, Chao Pan   +9 more
doaj   +1 more source

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment

Journal of Evidence-Based Medicine, Volume 19, Issue 2, June 2026.
ABSTRACT The rapid advancement of radiotherapy techniques and systemic anticancer agents has created unprecedented opportunities to improve outcomes for breast cancer patients, while also introducing new challenges related to optimal integration and safety.
Jie Lan, Wenyi Zhou, Qiufan Zheng, Lu Cao, Wenyan Chen, Zhenyu He, Chunling Jiang, Yanchu Li, Wen Xia, Huihua Xiong, Xiaoli Yu, Jun Zhang, Jianli Zhao, Yanxia Zhao, Lei Liu, Xin Wu, Shusen Wang, Xiaobo Huang, Jing Jing   +18 more
wiley   +1 more source

Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)

Radiation Oncology
Introduction Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary ...
Takaaki Tokito, Kazuhiko Yamada, Hidenobu Ishii, Yuichi Takiguchi, Go Saito, Koichi Minato, Hisao Imai, Hiroshi Tanaka, Satoru Miura, Kageaki Watanabe, Yoshifusa Koreeda, Akira Ono, Naoki Furuya, Toshihiro Misumi, Kazushige Hayakawa, Etsuyo Ogo, Hiroaki Okamoto   +16 more
doaj   +1 more source

Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival

BMC Cancer, 2020
Background Successful local therapy for oligometastases may lead to longer survival. The purpose of this multicentre retrospective study was to investigate factors affecting the local control (LC) of pulmonary oligometastases treated by stereotactic body
Takaya Yamamoto, Yuzuru Niibe, Masahiko Aoki, Takashi Shintani, Kazunari Yamada, Mitsuru Kobayashi, Hideomi Yamashita, Masatoki Ozaki, Yoshihiko Manabe, Hiroshi Onishi, Katsuya Yahara, Atsushi Nishikawa, Kuniaki Katsui, Ryoong-Jin Oh, Atsuro Terahara, Keiichi Jingu   +15 more
doaj   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer

Cancer Medicine, 2019
Purpose The aim of the study was to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for pulmonary lesions in oligometastatic non‐small cell lung cancer (NSCLC) patients, to explore prognostic factors of progression‐free survival
Wen Ouyang, Jing Yu, Shuake Nuerjiang, Zhijun Li, Dajiang Wang, Xiaoyong Wang, Junhong Zhang, Conghua Xie   +7 more
doaj   +1 more source

Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients

Respiratory Research, 2019
Background Although development of immune checkpoint inhibitors and various molecular target agents has extended overall survival time (OS) in advanced non-small cell lung cancer (NSCLC), a complete cure remains rare.
Takuya Aoki, Takeshi Akiba, Jun Nishiyama, Sakurako Tajiri, Naoki Hayama, Genki Takahashi, Jun Tanaka, Masako Sato, Hiroto Takiguchi, Hiromi Tomomatsu, Katsuyoshi Tomomatsu, Takahisa Takihara, Kyoko Niimi, Tsuyoshi Oguma, Mitsutomo Kohno, Ryota Masuda, Tetsuya Urano, Hitoshi Itoh, Hiroshi Kajiwara, Naoya Nakamura, Etsuo Kunieda, Mitsunori Matsumae, Masayuki Iwazaki, Koichiro Asano   +23 more
doaj   +1 more source

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China

Frontiers in Oncology, 2022
ObjectiveTo assess the efficacy and safety of stereotactic body radiation therapy (SBRT) in managing oligometastases of prostate cancer. Moreover, it is the largest-to-date study in China to report the safety and efficacy of SBRT by CyberKnife for ...
Chenyang Xu, Xianzhi Zhao, Xiaoping Ju, Yuxin Shen, Min Qu, Yusheng Ye, Xiaoyan Wang, Chunshan Yu, Xu Gao, Huojun Zhang   +9 more
doaj   +1 more source

Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first‐line treatment in patients
Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang   +9 more
wiley   +1 more source